Zoetis Inc. (NYSE:ZTS) Shares Acquired by Prudential PLC

Prudential PLC raised its holdings in Zoetis Inc. (NYSE:ZTS - Free Report) by 12.1% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 151,546 shares of the company's stock after buying an additional 16,327 shares during the period. Prudential PLC's holdings in Zoetis were worth $24,691,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of ZTS. Vanguard Group Inc. raised its holdings in Zoetis by 0.3% in the fourth quarter. Vanguard Group Inc. now owns 41,366,877 shares of the company's stock valued at $6,739,905,000 after acquiring an additional 120,158 shares in the last quarter. State Street Corp raised its holdings in shares of Zoetis by 0.5% in the 3rd quarter. State Street Corp now owns 19,779,344 shares of the company's stock valued at $3,864,488,000 after purchasing an additional 95,856 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Zoetis by 1.8% during the 4th quarter. Geode Capital Management LLC now owns 10,617,897 shares of the company's stock worth $1,726,075,000 after purchasing an additional 190,137 shares during the last quarter. Polen Capital Management LLC grew its stake in shares of Zoetis by 17.5% during the fourth quarter. Polen Capital Management LLC now owns 7,483,194 shares of the company's stock worth $1,219,237,000 after purchasing an additional 1,116,541 shares in the last quarter. Finally, Wellington Management Group LLP increased its holdings in Zoetis by 78.5% in the fourth quarter. Wellington Management Group LLP now owns 6,958,543 shares of the company's stock valued at $1,133,755,000 after buying an additional 3,059,255 shares during the last quarter. Institutional investors and hedge funds own 92.80% of the company's stock.

Remove Ads

Zoetis Stock Performance

NYSE ZTS traded down $2.70 during trading on Monday, reaching $149.03. The company's stock had a trading volume of 4,263,169 shares, compared to its average volume of 2,601,967. The business's fifty day moving average price is $165.71 and its 200-day moving average price is $173.26. Zoetis Inc. has a twelve month low of $144.07 and a twelve month high of $200.33. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.08 and a current ratio of 1.75. The firm has a market cap of $66.73 billion, a price-to-earnings ratio of 27.24, a P/E/G ratio of 2.78 and a beta of 0.92.

Zoetis (NYSE:ZTS - Get Free Report) last issued its quarterly earnings results on Thursday, February 13th. The company reported $1.40 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.37 by $0.03. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. The firm had revenue of $2.32 billion for the quarter, compared to analysts' expectations of $2.30 billion. As a group, analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be issued a dividend of $0.50 per share. This represents a $2.00 annualized dividend and a dividend yield of 1.34%. The ex-dividend date is Monday, April 21st. Zoetis's dividend payout ratio is presently 36.56%.

Insider Buying and Selling at Zoetis

In other Zoetis news, EVP Roxanne Lagano sold 326 shares of Zoetis stock in a transaction that occurred on Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total value of $55,804.68. Following the sale, the executive vice president now owns 16,107 shares of the company's stock, valued at approximately $2,757,196.26. The trade was a 1.98 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Willie M. Reed sold 1,210 shares of the business's stock in a transaction that occurred on Tuesday, March 11th. The stock was sold at an average price of $166.14, for a total value of $201,029.40. Following the transaction, the director now owns 11,245 shares in the company, valued at $1,868,244.30. The trade was a 9.71 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 1,862 shares of company stock valued at $312,254. 0.16% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of analysts have issued reports on ZTS shares. Morgan Stanley decreased their price target on Zoetis from $243.00 to $238.00 and set an "overweight" rating for the company in a report on Friday, February 14th. Barclays upped their price target on Zoetis from $242.00 to $244.00 and gave the company an "overweight" rating in a report on Friday, February 14th. StockNews.com raised shares of Zoetis from a "hold" rating to a "buy" rating in a report on Friday, March 7th. Stifel Nicolaus lowered their target price on shares of Zoetis from $210.00 to $180.00 and set a "buy" rating for the company in a report on Tuesday, January 7th. Finally, Piper Sandler lifted their price target on shares of Zoetis from $200.00 to $205.00 and gave the stock an "overweight" rating in a research note on Thursday, February 27th. One analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, Zoetis has an average rating of "Buy" and an average target price of $215.90.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.